Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank:DB05501_nanopub.RArEXlg3O0N1wGZti24WJiSKXMVIKrzFgpiTaPszMfxio#assertion>. }
Showing items 1 to 12 of
12
with 100 items per page.
- drugbank:DB05501 type drugbank_vocabulary:Drug assertion.
- drugbank:DB05501 label "AMD-070 [drugbank:DB05501]" assertion.
- drugbank:DB05501 seeAlso DB05501 assertion.
- drugbank:DB05501 description "AMD-070 is a small molecule drug candidate that belongs to a new investigational class of anti-HIV drugs known as entry (fusion) inhibitors. Currently there is only one FDA-approved entry inhibitor, enfuvirtide (Fuzeon), that is available for the treatment of HIV infection. Several experimental entry inhibitors are now in early stage testing, including AMD-070, which targets the CXCR4 receptor on HIV and prevents the virus from entering and infecting healthy cells. Other entry inhibitors target the CCR5 receptor of HIV.These new agents are widely viewed as next generation anti-HIV drugs with the potential to significantly advance HIV therapeutics." assertion.
- drugbank:DB05501 identifier "drugbank:DB05501" assertion.
- drugbank:DB05501 title "AMD-070" assertion.
- drugbank:DB05501 drugbank_vocabulary:x-cas cas: assertion.
- drugbank:DB05501 drugbank_vocabulary:drugbank-id "DB05501" assertion.
- drugbank:DB05501 bio2rdf_vocabulary:x-identifiers.org DB05501 assertion.
- drugbank:DB05501 bio2rdf_vocabulary:uri "http://bio2rdf.org/drugbank:DB05501" assertion.
- drugbank:DB05501 bio2rdf_vocabulary:namespace "drugbank" assertion.
- drugbank:DB05501 bio2rdf_vocabulary:identifier "DB05501" assertion.